Nomad Power Solutions (NMAD) Receivables - Other (2010 - 2020)
Nomad Power Solutions (NMAD) posted Receivables - Other of $76898.0 for Q4 2020, up 26881.75% on a QoQ basis from $285.0 in Q1 2020, and up 435.24% year-over-year from $14367.0 in Q1 2020.
Powered by 
Analysis
Nomad Power Solutions (NMAD) Receivables - Other (2010 - 2020) Analysis & Trends
Nomad Power Solutions has reported Receivables - Other for 3 years, with the latest figure at $76898.0 in Q4 2020.
- On a quarterly basis, Receivables - Other rose 435.24% year-over-year to $76898.0 in Q4 2020; TTM through Dec 2020 was $76898.0, a 435.24% increase from a year earlier, with the FY2020 full-year figure at $76898.0, up 435.24% from the prior year.
- Receivables - Other was $76898.0 for Q4 2020 at Nomad Power Solutions, up from $285.0 in the prior quarter.
- The five-year high for Receivables - Other was $76898.0 in Q4 2020, with the low at $285.0 in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Nomad Power Solutions | 49.59 Mn | 49.59 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 76,898.00 |
| Mar 31, 2020 | 285.00 |
| Dec 31, 2019 | 14,367.00 |
| Sep 30, 2019 | 21,974.00 |
| Jun 30, 2019 | 17,071.00 |
| Mar 31, 2019 | 4,161.00 |
| Dec 31, 2010 | 116,485.00 |